A recombinant FVIII to prevent and control bleeding in people with hemophilia A1
Now available
Novoeight® delivers
the reliability he needs
0
INHIBITORS
CONFIRMED1
One of the largest clinical trials with
no inhibitors confirmed in 213 PTPsa,b
Because he’s always looking ahead, he needs a treatment he can rely on.
Introduce him to Novoeight®, an evolution in treatment that had zero
inhibitors confirmed in PTPs.1,a,b
Malcolm, 18 years old, lives with hemophilia A.
Visit NovoeightPro.com to learn about
additional features and see how Novoeight®
can fit into his world.
PTPs=previously treated patients.
a
Patients with previous inhibitors were excluded from the trial. Individuals with hemophilia A may develop inhibitors to FVIII. Monitor patients taking Novoeight ® for inhibitor formation.1
b
guardian™1: a multicenter, multinational, open-label, single-arm efficacy and safety trial in 150 patients (aged 12 to 65 years) with severe hemophilia A on a prophylactic treatment regimen who
were exposed to turoctocog alfa for a mean of 85 exposure days (ranging from 11 to 172 exposure days), which corresponds to approximately 6 months in the trial. 2
guardian™3: a multicenter, multinational, noncontrolled, open-label safety, efficacy, and pharmacokinetic trial in 63 previously treated pediatric patients (aged 0 to 11 years) with hemophilia A
in which patients were exposed to turoctocog alfa for a mean of 60 exposure days (ranging from 20 to 104